roflumilast oral COPD
Selected indexed studies
- Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma. (Expert Opin Investig Drugs, 2008) [PMID:18447606]
- BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. (Front Pharmacol, 2022) [PMID:35517783]
- 2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPD. (Chest, 2023) [PMID:37690008]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. (2010) pubmed
- [Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review. (2024) pubmed
- Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma. (2008) pubmed
- BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. (2022) pubmed
- 2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPD. (2023) pubmed
- Oral Roflumilast Suppresses Proinflammatory Cytokine Signaling and Reduces CD4+ T-Cell and Neutrophil Infiltration in Psoriasis. (2025) pubmed
- Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology. (2025) pubmed
- Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial. (2011) pubmed
- Efficacy and Safety of Roflumilast in Korean Patients with COPD. (2016) pubmed
- Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO). (2023) pubmed